Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025)

Pyxis Oncology's (PYXS) quarterly Cost of Revenue came in at $2.4 million in Q4 2025, up 402.74% on a QoQ basis from $475000.0 in Q1 2024.

Pyxis Oncology (PYXS) Cost of Revenue (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of Cost of Revenue data on file, last reported at $2.4 million in Q4 2025.

On a quarterly basis, Cost of Revenue changed N/A year-over-year to $2.4 million in Q4 2025; TTM through Dec 2025 was $2.4 million, a 402.74% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 402.74% from the prior year.
Cost of Revenue for Q4 2025 stood at $2.4 million, up from $475000.0 in the prior quarter.
Over the last five years, Cost of Revenue for PYXS reached as high as $2.4 million in Q4 2025 and fell as low as $475000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	167.22 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	392.80 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	296.00 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	145.00 Mn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Pyxis Oncology	182.39 Mn	115.53 Mn	8.65 Mn	2.39 Mn

Download Data